ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Hypersensitivity
Adenocarcinoma
Recurrence
Castration-Resistant Prostatic Cancer

Prostate Cancer trials near Paris, Île-de-France, FRA:

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

primary trial objective is to demonstrate that ODM-201 produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥80% ...

Active, not recruiting
Prostate Cancer
Drug: ODM-201
Drug: ADT

Phase 2

European Organisation for Research and Treatment of Cancer (EORTC)

Villejuif, France and 11 other locations

This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisi...

Enrolling
Prostatic Disease
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Drug: Gedatolisib
Drug: Darolutamide

Phase 1, Phase 2

Celcuity

Villejuif, France and 12 other locations

to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate...

Enrolling
Prostate Cancer
Drug: Association of darolutamide and EBRT
Drug: Association of ADT and EBRT

Phase 2

Institut Bergonié

Paris, France and 9 other locations

with surgery in patients with high-risk and/or locally advanced prostate cancer.In this trial, patients will be assigned in one of ...

Enrolling
Prostate Cancer
Other: Surgery alone
Drug: Peri-operative darolutamide + surgery.

Phase 2

Institut Claudius Regaud

Paris, France and 16 other locations

Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA val...

Active, not recruiting
Prostate Cancer Metastatic
Drug: ARV-110 in Combination with Abiraterone

Phase 1

Arvinas
Arvinas

Paris, France and 17 other locations

Locations recently updated

the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate...

Enrolling
Prostate Cancer
Device: SpaceOAR Vue System
Boston Scientific
Boston Scientific

Villejuif, Cedex, France and 27 other locations

To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Active, not recruiting
Neuroendocrine Prostate Cancer
Drug: Tarlatamab

Phase 1

Amgen
Amgen

Villejuif Cedex, France and 20 other locations

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount ...

Active, not recruiting
Prostate Cancer
Drug: triptorelin
Procedure: adjuvant therapy

Phase 3

Unicancer
Unicancer

Paris, France and 16 other locations

docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate...

Active, not recruiting
Metastatic Prostate Cancer
Drug: Docetaxel
Radiation: radiotherapy

Phase 3

Unicancer
Unicancer

Paris, France and 76 other locations

plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednison...

Active, not recruiting
Prostate Cancer
Drug: Prednisone
Drug: Placebo

Phase 2, Phase 3

Lilly
Lilly

Créteil, Île-de-France, France and 111 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems